Axsome stocktwits.

846.4k shares, +14.9% compared to typical daily volume over the past 6 months. Typical daily volume is 736.6k shares over the past 6 months. Typical: 10.87 pts (14.1%) occurs 25% of the time. Extreme: 14.13 pts (18.4%) occurs 5% of the time. A summary of bullish and bearish indicators.Axsome AXSM announced that it is floating a secondary issue of 3 million shares of its common stock to the public at a price of $75.00 per share (excluding underwriting discounts).We are committed to developing products that meaningfully improve the lives of patients. Axsome is developing innovative treatments including AXS-05, AXS-07, AXS-12, and AXS‑14. learn about our pipeline. Axsome focuses on CNS conditions including depression, Alzheimer's disease agitation, migraine, narcolepsy and fibromyalgia.At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.Find real-time AXSM - Axsome Therapeutics Inc stock quotes, company profile, news and forecasts from CNN Business.

Axsome stock has a high Relative Strength Rating of 97, putting shares in the top 3% of all stocks in terms of 12-month performance, according to IBD Digital. Follow Allison Gatlin on Twitter at ...

Evotec Reddit Threads. Corcept Therapeutics Reddit Threads. MoonLake Immunotherapeutics Reddit Threads. Indivior Reddit Threads. Social Media Tools: Trending Media Mentions. High Media Sentiment Stocks. Trending WallStreetBets Stocks. This page (NASDAQ:AXSM) was last updated on 9/14/2023 by MarketBeat.com Staff.

Get the latest Axsome Therapeutics Inc (AXSM) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions.$66.51 $3.68 (5.24%) Today About Feed News Sentiment Earnings Fundamentals Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which engages in the development of novel therapies for the management of central nervous system disorders. Its portfolio consists of Products Overview and Pipeline Overview.Net sales of Sunosi to Axsome were $19.2 million and $44.8 million for the fourth quarter and full year of 2022 respectively. Axsome began selling Sunosi in the U.S. in May 2022 and in certain international markets in November 2022. Therefore no Sunosi sales were reported by Axsome for the 2021 comparable periods. Total cost of product sales ...Home - Plus Therapeutics (PSTV) Power and precision. in cancer. radiotherapeutics. Radiation is considered one of the most powerful methods of destroying cancer for over a century. But even today, ways to deliver significant doses to a tumor without damaging normal surrounding tissue are few. We are breaking that barrier with our new class of ...

As a matter of fact, the issue price is at an almost 11% discount to the closing price on Jun 27, wherein the stock closed at $83.37 per share. Axsome’s shares nosedived 2.8% year to date ...

Horizon Therapeutics. NEWS: Amgen completes acquisition of Horizon Therapeutics. Read press release. Our Company. Our Science. Our Medicines. Our Patients. Careers. Horizon Therapeutics is a biotechnology company that is driven to deliver breakthrough medicines to patients because we understand the challenges they face.

Axsome Therapeutics is a biopharmaceutical company focused on developing novel therapies for the management of central nervous system (CNS), disorders for which there are limited treatment options available. See More. AXSM Related stocks. Symbol 3M %Chg ; AXSM -7.18% : Axsome Thera: AMGN +19.95% : Amgen Inc: BMY6 Wall Street analysts have issued 1-year price targets for Avadel Pharmaceuticals' stock. Their AVDL share price forecasts range from $11.00 to $25.00. On average, they predict the company's stock price to reach $18.14 in the next twelve months. This suggests a possible upside of 65.4% from the stock's current price.AXSM bought FDA approved SUNOSI from JAZZ in March. CNS Pipeline is AXS-05, AXS-07, AXS-12, AXS-14. AXS-05 is expected to be FDA approved in Q2 for Depression. AXSM’s new drug application (NDA) seeking approval for AXS-05 to treat MDD is under a priority review with the FDA. After a positive interaction with the regulatory agency’s ...According to 10 analyst offering 12-month price targets in the last 3 months, Axsome Therapeutics has an average price target of $118.4 with a high of $210.00 and a low of $52.00.Axsome Therapeutics expects peak sales of between $1 billion and $3 billion in the U.S. for AXS-05 in this indication were it to be approved. The drug is also being investigated as a potential ...

Axsome Therapeutics, Inc. Common Stock (AXSM) Pre-Market Stock Quotes - Nasdaq offers pre-market quotes and pre-market activity data for US and global markets.That is to say, Axsome disclosed in August 2021 that the FDA would not complete its review of Auvelity for MDD before the former Prescription User Drug Fee Act (PDUFA) date of August 22, 2021.Axsome Therapeutics (AXSM 1.40%), a newly minted commercial-stage biopharma, is set for a strong session today. Specifically, the company's shares are up by a whopping 52% in pre-market trading ...Shares of Axsome Therapeutics ( AXSM 1.09%) were soaring 12.7% higher as of 11:19 a.m. ET on Thursday. The company didn't report any new developments, so what's behind the nice gain? There are two ...Axsome stock has a high Relative Strength Rating of 97, putting shares in the top 3% of all stocks in terms of 12-month performance, according to IBD Digital. Follow Allison Gatlin on Twitter at ...Mexico - Mexico Delayed Price. Currency in MXN. Follow. 1,247.00 0.00 (0.00%) At close: 09:42AM CST. Find the latest Axsome Therapeutics, Inc. (AXSM.MX) stock discussion in Yahoo Finance's forum ...

According to 10 analyst offering 12-month price targets in the last 3 months, Axsome Therapeutics has an average price target of $118.4 with a high of $210.00 and a low of $52.00.Axsome Therapeutics ( AXSM 1.09%), a clinical-stage biotech focused on the development of drugs for central nervous system disorders, had a seriously rough August. The biotech's shares slipped by ...

In August, Axsome received FDA approval for its lead pipeline candidate AXS-05, with the trade name of Auvelity, for the treatment of adults with major depressive disorder (MDD), making it the ...Axsome Therapeutics (NASDAQ:AXSM) is a great speculative biotech to look into. ... You can follow me on stocktwits.com under the name BiopharmaPro where I currently have (62.5K) followers. ...StockTwits is a social media platform designed for sharing ideas between investors, traders, and entrepreneurs. The company was co-founded by Howard Lindzon and Soren Macbeth in 2009. The company received the first Shorty Award in the 2008 finance category. Time magazine listed the company as one of its 2010 "50 best websites." The company …Axsome won regulatory approval for Auvelity and launched the drug in the fall of last year. Each drug could generate peak revenue of more than $1 billion, according to company and analyst forecasts.View live Axsome Therapeutics, Inc. chart to track its stock's price action. Find market predictions, AXSM financials and market news.In August, Axsome received FDA approval for its lead pipeline candidate AXS-05, with the trade name of Auvelity, for the treatment of adults with major depressive disorder (MDD), making it the ...

Axsome Contact: Mark Jacobson Chief Operating Officer Axsome Therapeutics, Inc. 22 Cortlandt Street, 16th Floor New York, NY 10007 Tel: 212-332-3243 Email: [email protected]

The consensus estimate for Axsome Therapeutics’ full-year earnings is currently projected at ($4.01) per share. Additionally, Zacks Research provided estimates for Axsome Therapeutics’ future earnings, stating that their predicted earnings for the fourth quarter of 2023 will be ($1.41) per share and ($4.30) per share for fiscal year 2023.

Axsome Contacts: Investors: Mark Jacobson Chief Operating Officer Axsome Therapeutics, Inc. One World Trade Center, 22 nd Floor New York, NY 10007 Tel: 212-332-3243 Email: [email protected] the latest Axsome Therapeutics, Inc. (AXSM) stock analysis from Seeking Alpha’s top analysts: exclusive research and insights from bulls and bears.Get the latest Axsome Therapeutics Inc. (AXSM) stock price, news, buy or sell recommendation, and investing advice from Wall Street professionals.il y a 1 jour ... Share on Twitter Share on Facebook Share on LinkedIn Share on Stocktwits. Axsome Therapeutics logo Teacher Retirement System of Texas ...Featured Post From StockTwits About AXSM. $AXSM following up with @theJew post on job postings. Asked my coworker about his wife and if he ever heard back from AXSM. He said they had a second call and he thinks she asked for too much in …View Axsome Therapeutics, Inc AXSM investment & stock information. Get the latest Axsome Therapeutics, Inc AXSM detailed stock quotes, stock data, Real-Time ECN, charts, stats and more.View Axsome Therapeutics, Inc AXSM investment & stock information. Get the latest Axsome Therapeutics, Inc AXSM detailed stock quotes, stock data, Real-Time ECN, charts, stats and more.Auvelity is Axsome’s first drug approved by the FDA in August 2021 and launched in October 2022. Sunosi net product sales were $12.9 million for the first quarter of 2023. There were no net ...Crispr is a specialist in gene editing, or the repair of faulty genes responsible for disease. The company has reached an exciting moment, with the possibility of its first product launch just months away. Find the latest Axsome Therapeutics, Inc. (AXSM) stock quote, history, news and other vital information to help you with your stock trading ...

Axsome Therapeutics Inc reported a loss of $1.26 per share in the current quarter. However, the company generated $40.7 million in sales. Investors are eagerly awaiting the reporting date of August 09, when Axsome Therapeutics Inc will release its detailed financial results for the quarter.StockTwits is a social network designed specifically for traders and investors to share ideas in real-time. The platform adds a nice spin to the old “stock market message boards” model with a more efficient platform and additional features. Read through this review to see if StockTwits is worth your time or if you’re better off avoiding ...Axsome is a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system disorders. AXSM Price Action: Axsome has a 52-week high of $71.98 and a 52-week low of $20.63. The stock was up 17.1% at $66.55 at time of publication, according to Benzinga Pro. 1 Reply. Instagram:https://instagram. heb 290 and barker cypressploss auctionshoney on bluntcar games unblocked unity Get Our Latest Analysis on AXSM. Axsome Therapeutics Stock Performance. AXSM stock opened at $70.19 on Wednesday. The company has a debt-to-equity ratio of 0.63, a current ratio of 4.52 and a ...83.56 +0.65(+0.78%) Gold 1,886.00 +3.00(+0.16%) Advertisement Axsome Therapeutics, Inc. (AXSM) NasdaqGM - NasdaqGM Real Time Price. Currency in USD Follow 2W 10W 9M 66.51 -3.68 (-5.24%) At close:... single family homes for rent in anchorage akerin o'brien scituate Axsome Therapeutics: 'Buy' The Auvelity Launch (Rating Upgrade) by Stephen Ayers David Single AXSM is a bright spot and IMHO will become a very profitable investment for those with patience. troy record obituaries troy new york Bank of America Corporation Common Stock. $30.45 -0.10 0.33%. Axsome Therapeutics, Inc. Common Stock (AXSM) Pre-Market Stock Quotes - Nasdaq offers pre-market quotes and pre-market activity data ...83.56 +0.65(+0.78%) Gold 1,886.00 +3.00(+0.16%) Advertisement Axsome Therapeutics, Inc. (AXSM) NasdaqGM - NasdaqGM Real Time Price. Currency in USD Follow 2W 10W 9M 66.51 -3.68 (-5.24%) At close:...Axsome Therapeutics, Inc. Fed, Rising Energy Costs Pressure Stocks The Portfolio Selector features the Argus Focus List, a group of 30 "best idea" stocks generated and regularly updated by Argus ...